Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

License Agreements (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
License Agreements (Details) - USD ($) $ in Thousands	Jul. 31, 2026	May 31, 2026	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Aug. 31, 2026	Oct. 31, 2025	May 31, 2021	Oct. 31, 2020
Nature of Business
Acquired in-process research and development			$ 27,500	$ 5,000	$ 57,500	$ 5,000
2021 Xencor Agreement
Nature of Business
Regulatory milestone payments									$ 62,500
Sales milestone payments									385,000
License and option agreements, Food and Drug Administration market authorization milestone payments made		$ 10,000
Acquired in-process research and development			2,500	0	12,500	0
Regulatory milestone payments made	$ 2,500
2021 Xencor Agreement \| Market Approval By U S Food And Drug Administration [Member]
Nature of Business
License and option agreements, Food and Drug Administration market approval payable									20,000
2021 Xencor Agreement \| Market Approval By European Medicines Agency [Member]
Nature of Business
License and option agreements, Food and Drug Administration market approval payable									$ 15,000
Viridian Agreement
Nature of Business
Sales milestone payments										$ 21,000
Contract manufacturing organization costs recognized			0	$ 0	0	0
Reimbursable costs			0		0	$ 200
InnoCare Pharma Inc
Nature of Business
Non-refundable cash payment								$ 35,000
Number of shares agreed to be issued								5,000,000
Number of additional shares agreed to be issued							2,000,000
Acquired in-process research and development			25,000		45,000
Term milestone payments							$ 25,000	$ 20,000
Future regulatory and commercial milestones payable								723,000
Regulatory milestone payments made		$ 20,000
Contract manufacturing organization costs recognized			3,100		5,000
Reimbursable costs			$ 700		$ 2,900
InnoCare Pharma Inc \| ZB021
Nature of Business
Development, regulatory and commercial milestones payable								636,000
InnoCare Pharma Inc \| ZB022
Nature of Business
Development, regulatory and commercial milestones payable								$ 656,000